非阿司匹林类非甾体抗炎药使用与卵巢癌死亡率的关系
丹麦全国性队列研究纳入2000至2012年首次诊断上皮性卵巢癌的4117例患者,分析诊断后非阿司匹林类非甾体抗炎药(NSAID)使用与卵巢癌特异性死亡的关系。诊断后任何使用与卵巢癌死亡率无关(HR=0.97,95%CI=0.87-1.08),但高累积或高强度使用与卵巢癌死亡率呈反向关联,且关联因组织学亚型而异。
要点
- 诊断后任何非阿司匹林类NSAID使用与卵巢癌死亡率无关(HR=0.97,95%CI=0.87-1.08)。
- 高累积使用与卵巢癌死亡率呈反向关联(HR=0.75,95%CI=0.60-0.94)。
- 仅浆液性卵巢癌中观察到反向关联(HR=0.87,95%CI=0.77-0.99)。
核心结论
- 诊断后任何非阿司匹林类NSAID使用总体上不影响卵巢癌死亡率,但更密集的使用与浆液性卵巢癌生存改善相关。
研究设计与样本
- 丹麦全国性注册登记队列研究,纳入2000至2012年首次诊断上皮性卵巢癌的全部女性,共4117例患者。
主要发现
- 诊断后任何非阿司匹林类NSAID使用与卵巢癌死亡率无关(HR=0.97,95%CI=0.87-1.08),与其他原因死亡率亦无关(HR=0.99,95%CI=0.77-1.27)。
- 高累积使用与卵巢癌死亡率呈反向关联(HR=0.75,95%CI=0.60-0.94),高强度使用呈反向关联(HR=0.86,95%CI=0.72-1.03)。
- 仅浆液性卵巢癌中观察到反向关联(HR=0.87,95%CI=0.77-0.99)。
- 在较少数非浆液性肿瘤患者中,诊断后非阿司匹林类NSAID使用与卵巢癌死亡率增加相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Preclinical studies suggest that non-aspirin non-steroidal anti-inflammatory drugs (NSAIDs) may improve survival of ovarian cancer. We examined the association between non-aspirin NSAID use and ovarian cancer mortality. METHODS: All women in Denmark with a first diagnosis of epithelial ovarian cancer between 2000 and 2012 were identified. We obtained information on drug use, mortality outcomes, and potential confounding factors from nationwide registries. Cox regression models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for the association between postdiagnosis non-aspirin NSAID use (≥1 prescription) and ovarian cancer-specific or other-cause mortality compared with non-use (no prescriptions). The influence of competing risks was evaluated using the sub-distribution hazards model proposed by Fine and Gray. RESULTS: Among 4117 patients, any postdiagnosis use of non-aspirin NSAIDs was not associated with either ovarian cancer (HR = 0.97, 95% CI = 0.87-1.08) or other-cause (HR = 0.99, 95% CI = 0.77-1.27) mortality, however, inverse associations for ovarian cancer mortality were observed with high cumulative (HR = 0.75, 95% CI = 0.60-0.94) or high-intensity (HR = 0.86, 95% CI = 0.72-1.03) postdiagnosis use of non-aspirin NSAIDs. The associations differed substantially with histological subtype of ovarian cancer, with only inverse associations observed for serous ovarian cancer (HR = 0.87, 95% CI = 0.77-0.99). Among a smaller number of patients with a non-serous tumor, postdiagnosis non-aspirin NSAID use was associated with increased ovarian cancer mortality. CONCLUSIONS: Any postdiagnosis use of non-aspirin NSAIDs did not influence ovarian cancer mortality overall, however, more intensive use was associated with improved survival of serous ovarian cancer.
引用
- Verdoodt F, Dehlendorff C, Friis S, et al. Non-aspirin NSAID use and ovarian cancer mortality. Gynecol Oncol. 2018. PMID: 29960709. doi:10.1016/j.ygyno.2018.06.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。